ImpactU Versión 3.11.2 Última actualización: Interfaz de Usuario: 16/10/2025 Base de Datos: 29/08/2025 Hecho en Colombia
Efficacy of Ixekizumab Versus Adalimumab in Psoriatic Arthritis (PsA) Patients With and Without Moderate-to-Severe Psoriasis: 52-Week Results from a Multicentre, Randomised Open-Label Study
Efficacy of Ixekizumab Versus Adalimumab in Psoriatic Arthritis ( PsA) Patients With and Without Moderate-to- Severe Psoriasis: 52-Week Results from a Multicentre, Randomised Open-Label Study logo search JOURNAL OF RHEUMATOLOGY Publication date: 2021-07 Volume: 48 Pages: 1167 - 1168 ISSN: 0315-162X, 1499-2752 Publisher: The Journal of Rheumatology Publishing Co. Ltd. Efficacy of Ixekizumab Versus Adalimumab in Psoriatic Arthritis ( PsA) Patients With and Without Moderate-to- Severe Psoriasis: 52-Week Results from a Multicentre
